Pembrolizumab-induced fulminant type 1 diabetes mellitus: a case report and literature review.
- 1Weifang People's Hospital, Shandong Second Medical University, Weifang, China.
- 2Department of Arrhythmia, Weifang People's Hospital, Shandong Second Medical University, Weifang, China.
- 3Department of Endocrinology, Weifang People's Hospital, Shandong Second Medical University, Weifang, China.
Abstract
As pembrolizumab has been widely used in the immunotherapy of various solid tumors such as melanoma and lung cancer, reports of pembrolizumab-related adverse drug events have gradually attracted attention; however, cases of pembrolizumab-induced fulminant type 1 diabetes mellitus (FT1DM) remain rare. This article reports a case of a young male patient with clear cell renal cell carcinoma (ccRCC) and suspected pulmonary metastases, who had a prior history of hypothyroidism and no family history of diabetes. After 22 cycles of pembrolizumab treatment, the patient developed lethargy and marked metabolic acidosis. The patient had markedly elevated blood glucose with an HbA1c of 6.7% and extremely low C-peptide levels. Given the history of pembrolizumab treatment, the patient was diagnosed with immune checkpoint inhibitor-associated FT1DM. His condition improved after fluid resuscitation and insulin therapy, and he was subsequently discharged. The patient continued treatment with the same agent for another three cycles before permanent discontinuation. Given the rarity of pembrolizumab-associated FT1DM, we further reviewed the literature. A literature search identified 32 confirmed cases of pembrolizumab-associated FT1DM, which were included in the analysis. The 32 reported cases mainly involved lung cancer and melanoma, with FT1DM onset ranging from 1 to 24 treatment cycles. GADA-positive patients tended to develop FT1DM earlier. Thyroid dysfunction occurred before or concurrently with FT1DM in 90% of cases. One case of pituitary dysfunction and one case of adrenal dysfunction both occurred after FT1DM onset. These findings suggest that metabolic monitoring should continue throughout pembrolizumab therapy, and that subsequent endocrine dysfunction should be monitored after FT1DM. Pembrolizumab-associated FT1DM requires long-term insulin therapy. Whether to continue or resume pembrolizumab should be decided individually after DKA resolution and glycemic stabilization.
Related
- Acquired generalized lipodystrophy complicated by fulminant type 1 diabetes mellitus: a case report with review of literature and immunological insights
- Transient pancreatic enlargement with peripancreatic inflammatory changes two days before clinical presentation and diagnosis of atezolizumab-related fulminant type 1 diabetes mellitus followed by pancreatic atrophy: a case report with review of literature
- CFTR variant-associated hereditary pancreatitis complicated by diabetes mellitus: a case report and literature review
- Escherichia Coli–associated Emphysematous Pyelonephritis in Previously Undiagnosed Type 2 Diabetes Mellitus Requiring Nephrectomy: A Case Report and Review of Literature
- Arginine vasopressin deficiency following pembrolizumab-induced hypophysitis: a case report and review of the literature
BibTeX
@article{sun2026pembrolizumabinduced,
title = {{Pembrolizumab-induced fulminant type 1 diabetes mellitus: a case report and literature review.}},
author = {Shujun Sun and Liang Su and Xiaojing Ma and Jianxin Dou},
journal = {Frontiers in endocrinology},
year = {2026},
month = oct,
doi = {10.3389/fendo.2026.1958726},
url = {https://europepmc.org/article/MED/42908608},
note = {CC BY},
}
RIS
TY - JOUR
TI - Pembrolizumab-induced fulminant type 1 diabetes mellitus: a case report and literature review.
AU - Shujun Sun
AU - Liang Su
AU - Xiaojing Ma
AU - Jianxin Dou
PY - 2026
DA - 2026/10/07
JO - Frontiers in endocrinology
DO - 10.3389/fendo.2026.1958726
UR - https://europepmc.org/article/MED/42908608
AB - As pembrolizumab has been widely used in the immunotherapy of various solid tumors such as melanoma and lung cancer, reports of pembrolizumab-related adverse drug events have gradually attracted attention; however, cases of pembrolizumab-induced fulminant type 1 diabetes mellitus (FT1DM) remain rare. This article reports a case of a young male patient with clear cell renal cell carcinoma (ccRCC) and suspected pulmonary metastases, who had a prior history of hypothyroidism and no family history of diabetes. After 22 cycles of pembrolizumab treatment, the patient developed lethargy and marked metabolic acidosis. The patient had markedly elevated blood glucose with an HbA1c of 6.7% and extremely low C-peptide levels. Given the history of pembrolizumab treatment, the patient was diagnosed with immune checkpoint inhibitor-associated FT1DM. His condition improved after fluid resuscitation and insulin therapy, and he was subsequently discharged. The patient continued treatment with the same agent for another three cycles before permanent discontinuation. Given the rarity of pembrolizumab-associated FT1DM, we further reviewed the literature. A literature search identified 32 confirmed cases of pembrolizumab-associated FT1DM, which were included in the analysis. The 32 reported cases mainly involved lung cancer and melanoma, with FT1DM onset ranging from 1 to 24 treatment cycles. GADA-positive patients tended to develop FT1DM earlier. Thyroid dysfunction occurred before or concurrently with FT1DM in 90% of cases. One case of pituitary dysfunction and one case of adrenal dysfunction both occurred after FT1DM onset. These findings suggest that metabolic monitoring should continue throughout pembrolizumab therapy, and that subsequent endocrine dysfunction should be monitored after FT1DM. Pembrolizumab-associated FT1DM requires long-term insulin therapy. Whether to continue or resume pembrolizumab should be decided individually after DKA resolution and glycemic stabilization.
SN - 1664-2392
ER -